Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRQIJO)

• Drug Name: Bepranemab Drug Info
• Synonyms: RG6416

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMRQIJO

Molecule-Related Drug Atlas

Drug(s) Targeting Microtubule-associated protein tau (MAPT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[3]
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[4]
TRx0237	DM0QNF4	Alzheimer disease	8A20	Phase 3	[5]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[6]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[7]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[8]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[4]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[8]
Semorinemab	DMA17VD	Alzheimer disease	8A20	Phase 2	[9]
JNJ-63733657	DMMKWGJ	Alzheimer disease	8A20	Phase 2	[10]
LMT-X	DMOFIBM	Acute myeloid leukaemia	2A60	Phase 3	[3]
Davunetide	DMD7K9X	Cognitive impairment	6D71	Phase 3	[4]
TRx0237	DM0QNF4	Alzheimer disease	8A20	Phase 3	[5]
E2814	DMZ3Q59	Alzheimer disease	8A20	Phase 2/3	[6]
PBT-2	DMKWGS1	Alzheimer disease	8A20	Phase 2	[7]
RG6100	DMEFD0B	Alzheimer disease	8A20	Phase 2	[8]
Tau-binding PET tracer	DM9QFW2	Alzheimer disease	8A20	Phase 2	[4]
BIIB092	DM263RP	Progressive supranuclear palsy	8A00.10	Phase 2	[8]
Semorinemab	DMA17VD	Alzheimer disease	8A20	Phase 2	[9]
JNJ-63733657	DMMKWGJ	Alzheimer disease	8A20	Phase 2	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Microtubule-associated protein tau (MAPT)	TTS87KH	TAU_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04867616) A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer's Disease (AD), Followed by an Open-Label Extension Period. U.S.National Institutes of Health.
• [2] Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
• [3] Clinical pipeline report, company report or official report of TauRx.
• [4] Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
• [5] Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
• [6] Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
• [7] PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
• [10] ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.